The whys and hows of hematopoietic progenitor and stem cell mobilization

Bone Marrow Transplantation

Volumn 31, Issue 5, 2003, Pages 319-329

  Kessinger, A ^a   Sharp, J G ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Mobilization; Progenitor; Stem cell

Indexed keywords

ANTINEOPLASTIC AGENT; BETA1 INTEGRIN; CD34 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; CYCLOPHOSPHAMIDE; CYTOKINE; ERYTHROPOIETIN; FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 3; INTERLEUKIN 6; MOLECULAR MARKER; RITUXIMAB; STEM CELL FACTOR; STROMAL CELL DERIVED FACTOR 1; VASCULAR CELL ADHESION MOLECULE 1;

ALLOTRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; AUTOTRANSPLANTATION; BLOOD CELL; BONE MARROW APLASIA; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CIRCULATION; CLINICAL OBSERVATION; CLINICAL TRIAL; CONVALESCENCE; DONOR; DOSE RESPONSE; DRUG EFFICACY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; METHODOLOGY; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SHORT SURVEY; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW; CYTOKINES; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS;

EID: 0037355362     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703837     Document Type: Short Survey

References (106)

1. Wintrobe M (ed.) Clinical Hematology, 5th edn. Lea and Febinger: Philadelphia, 1961.
2. Maximow A. Der Lymphozyt als gemeinsame Stammzelle der verschiedenen Blutelemente in der embryonalen Entwicklung und im postfetalen Leben der Saugetiere. Folia Hematol (Leipzig) 1909; 8: 125-141.
3. Malinin TI, Perry VP, Donlan MF. Some observations on the histology of lethally irradiated guinea pigs protected with nucleated elements of homologous blood. Blood 1963; 22: 499-500 (Abst).
4. Cavins JA, Scheer SC, Thomas ED, Ferrebee JW. The recovery of lethally irradiated dogs given infusions of autologous leukocytes preserved at -80°C. Blood 1964; 23: 38-42.
5. Rubin SH, Cowan DH. Assay of granulocytic progenitor cells in human peripheral blood. Exp Hematol 1973; 1: 127-131.
6. Barr RD, Whang-Peng J, Perry S. Hematopoietic stem cells in human peripheral blood. Science 1975; 190: 284-285.
7. Perry VP, Malinin TI, Kerby CC, Dolan MF. Protection of lethally irradiated guinea pigs with fresh and frozen homologous peripheral blood leukocytes. Cryobiology 1965; 1: 233-239.
8. Debelak-Fehir KM, Epstein RB. Restoration of hematopoiesis in dogs by infusion of cryopreserved autologous peripheral white cells following busulfan-cyclophosphamide treatment. Transplantation 1975; 20: 63-67.
9. Calvo W, Fliedner TM, Herbst E et al. Regeneration of blood forming organs after autologous leukocyte transfusion in lethally irradiated dogs. II. Distribution and cellularity of the marrow in irradiated and transfused animals. Blood 1976: 47: 593-601.
10. Storb R, Graham TC, Epstein RB et al. Demonstration of hematopoietic stem cells in the peripheral blood of baboons by cross circulation. Blood 1977; 50: 537-547.
11. Weiner RS, Richman CM, Yankee RA. Semicontinuous flow centrifugation for the pheresis of immunocompetent cells and stem cells. Blood 1977; 49: 391-397.
12. McCarthy DM, Goldman JM. Transfusion of circulating stem cells. CRC Crit Rev Clin Lab Sci 1984; 20: 1-24.
13. Kessinger A, Armitage JO, Landmark JD, Weisenburger DD. Reconstitution of human hematopoietic function with autologous cryopreserved circulating stem cells, Exp Hematol 1986; 14: 192-196.
14. Hershko C, Gale RP, Ho WG, Cline MJ. Cure of aplastic anaemia in paroxysmal nocturnal haemoglobinuria by marrow transfusion from identical twin: failure of peripheral-leukocyte transfusion to correct marrow aplasia. Lancet 1979; 1: 945-947.
15. Abrams RA, Glaubiger D, Appelbaum FR, Deisseroth AB. Result of attempted hematopoietic reconstitution using isologous peripheral blood mononuclear cells: a case report. Blood 1980; 56: 516-520.
16. Kessinger A, Vose JM, Bierman PJ, Armitage JO. High-dose therapy and autologous peripheral stem cell transplantation for patients with bone marrow metastases and relapsed lymphoma: an alternative to bone marrow purging. Exp Hematol 1991; 19: 1013-1016.
17. Richman CM, Weiner RS, Yankee RA. Increase in circulating stem cells following chemotherapy in man. Blood 1976; 47: 1031-1039.
18. To LB, Haylock DN, Kimber RJ, Juttner CA. High levels of circulating haemopoietic stem cells in very early remission from acute non-lymphoblastic leukaemia and their collection and cryopreservation. Br J Haematol 1984; 58: 399-410.
19. Juttner CA, To LB, Ho JQK et al. Early lympho-hemopoietic recovery after autografting using peripheral blood stem cells in acute non-lymphoblastic leukemia. Transplant Proc 1988; 20: 40-42.
20. Socinski MA, Cannistra SA, Elias A et al. Granulocyte-macrophage colony stimulating factor expands the circulating haemopoietic progenitor cell compartment in man. Lancet 1988; 1: 1194-1198.
21. Duhrsen U, Villeval J-L, Boyd J et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988; 72: 2074-2081.
22. LeCorroller AG, Faucher C, Auperin A et al. Autologous peripheral blood progenitor-cell transplantation versus autologous bone marrow transplantation for adults and children with non-leukemic malignant disease. A randomised economic study. Pharmacoeconomics 1997; 11: 454-463.
23. Russell NH, McQuaker G, Stainer C et al. Stem cell mobilisation in lymphoproliferative diseases. Bone Marrow Transplant 1998; 22: 935-940.
24. Narayanasami U, Kanteti R, Morelli J et al. Randomized trial of filgrastim versus chemotherapy and filgrastim mobilization of hematopoietic progenitor cells for rescue in autologous transplantation. Blood 2001; 98: 2059-2064.
25. Bensinger W, Appelbaum F, Rowley S et al. Factors that influence collection and engraftment of autologous peripheral-blood stem cells. J Clin Oncol 1995; 13: 2547-2555.
26. Demirer T, Buckner CD, Gooley T et al. Factors influencing collection of peripheral blood stem cells in patients with multiple myeloma. Bone Marrow Transplant 1996; 17: 937-941.
27. Koc ON, Gerson SL, Cooper BW et al. Randomized crossover trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol 2000; 18: 1824-1830.
28. Demirer T, Ayli M, Ozcan M et al. Mobilization of peripheral blood stem cells with chemotherapy and recombinant human granulocyte colony-stimulating factor (rhG-CSF): a randomized evaluation of different doses of rhG-CSF. Br J Haematol 2002; 116: 468-474.
29. Weaver CH, Schulman KA, Ketchum ID. Mobilization of peripheral blood stem cells following myelosuppressive chemotherapy: a randomized comparison of filgrastim, sargramostim, or sequential sargramostim and filgrastim. Bone Marrow Transplant 2001; 27: 23-29.
30. Gazitt Y, Callander N, Freytes CO et al. Peripheral blood stem cell mobilization with cyclophosphamide in combination with G-CSF, GM-CSF or sequential GM-CSF/G-CSF in non-Hodgkin's lymphoma patients: a randomized prospective study. J Hematother Stem Cell Res 2000; 9: 737-748.
31. Ballestrero A, Ferrando F, Garuti A et al. Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocytemacrophage colony-stimulating factor (GM-CSF) and sequential Interleukin-3 and GM-CSF. J Clin Oncol 1999; 17: 1296-1303.
32. Pierelli L, Perillo A, Greggi S et al. Erythropoietin addition to granulocyte colony-stimulating factor abrogates life-threatening neutropenia and increases peripheral-blood progenitor-cell mobilization after epirubicin, paclitaxel, and cisplatin combination chemotherapy: results of a randomized comparison. J Clin Oncol 1999; 17: 1288-1295.
33. Waller CF, von Lintig F, Daskalakis A et al. Mobilization of peripheral blood progenitor cells in patients with breast cancer: a prospective randomized trial comparing rhG-CSF with the combination of rhG-CSF plus rhEpo after VIP-E chemotherapy. Bone Marrow Transplant 1999; 24: 19-24.
34. Perillo A, Pierelli L, Scambia G et al. Peripheral blood progenitor cell collection after epirubicin, paclitaxel, and cisplatin combination chemotherapy using EPO-based cytokine regimens: a randomized comparison of G-CSF and sequential GM-/G-CSF. Transfusion 2001; 41: 674-680.
35. Grigg AP, Roberts AW, Raunow H et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood 1995; 86: 4437-4445.
36. Waller CF, Bertz H, Wenger MK et al. Mobilization of peripheral blood progenitor cells for allogeneic transplantation: efficacy and toxicity of a high-dose rhG-CSF regimen. Bone Marrow Transplant 1996; 18: 279-283.
37. Lee V, Li CK, Shing MMK et al. Single vs twice daily G-CSF dose for peripheral blood stem cells harvest in normal donors and children with non-malignant diseases. Bone Marrow Transplant 2000; 25: 931-935.
38. Sautois B, Baudoux E, Salmon JP et al. Administration of erythropoietin and granulocyte colony-stimulating factor in donor/recipient pairs to collect peripheral blood progenitor cells (PBPC) and red blood cell units for use in the recipient after allogeneic PBPC transplantation. Haematologica 2001; 86: 1209-1218.
39. DiPersio JF, Khoury H, Haug J et al. Innovations in allogeneic stem-cell transplantation. Semin Hematol 2000; 37 (Suppl. 2): 33-41.
40. Stiff PJ. Management strategies for the hard-to-mobilize patient. Bone Marrow Transplant 1999; 23 (Suppl. 2): S29-S33.
41. Shpall EJ, Wheeler CA, Turner SA et al. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood 1999; 93: 2491-2501.
42. Bishop MR, Anderson JR, Jackson JD et al. High-dose therapy and peripheral blood progenitor cell transplantation: effects of recombinant human granulocyte-macrophage colony-stimulating factor on the autograft. Blood 1994; 83: 610-616.
43. Kessinger A, Bishop MR, Anderson JR et al. Erythropoietin for mobilization of circulating progenitor cells in patients with previously-treated relapsed malignancies. Exp Hematol 1995; 23: 609-612.
44. Vose JM, Kessinger A, Bierman PJ et al. The use of rhIL-3 for mobilization of peripheral blood stem cells in previously treated patients with lymphoid malignancies. Int J Cell Cloning 1992; 10 (Suppl. 1): 62-64.
45. Bishop MR, Jackson JD, O'Kane-Murphy B et al. Phase I trial of recombinant fusion protein PIXY321 for mobilization of peripheral-blood cells. J Clin Oncol 1996; 14: 2521-2526.
46. Lebsack ME, McKenna HJ, Hoek JA et al. Safety of FLT3 ligand in healthy volunteers. Blood 1997; 90 (Suppl. 1): 170a (Abstr. 751).
47. Pettengell R, Luft T, de Wynter E et al. Effects of interleukin-6 on mobilization of primitive haemopoietic cells into the circulation. Br J Haematol 1995; 89: 237-242.
48. Siena S, Schiavo R, Pedrazzoli P, Carol-Stella C. Therapeutic relevance of CD34+ cell dose in blood cell transplantation for cancer therapy. J Clin Oncol 2000; 18: 1360-1377.
49. Watts MJ, Sullivan AM, Leverett D et al. Back-up bone marrow is frequently ineffective in patients with poor peripheral blood stem cell mobilization. J Clin Oncol 1998; 16: 1554-1560.
50. Ketterer N, Salles G, Raba M et al. High CD34+ cell counts decrease hematologic toxicity of autologous peripheral blood progenitor cell transplantation. Blood 1998; 91: 3148-3155.
51. Bensinger WI, Martin PJ, Storer B et al. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N Eng J Med 2001; 344: 175-181.
52. Singhal S, Powles R, Kulkarni S et al. Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation. Bone Marrow Transplant 2000; 25: 501-505.
53. 6 CD34 + cells/kg be considered the minimum threshold? Bone Marrow Transplant 2000; 26: 489-496.
54. Sharp JG, Kessinger A, Lynch JC et al. Blood stem cell transplantation: factors influencing cellular immunological reconstitution. J Hematother Stem Cell Res 2000; 9: 971-981.
55. Morariu-Zamfir R, Rocha V, Devergie A et al. Influence of CD34+ marrow cell dose on outcome of HLA-identical sibling allogeneic bone marrow transplants in patients with chronic myeloid leukemia. Bone Marrow Transplant 2001; 27: 575-580.
56. Zaucha JM, Gooley T, Bensinger WI et al. CD34 cell dose in granulocyte colony-stimulating factor-mobilized peripheral blood mononuclear cell grafts affects engraftment kinetics and development of extensive chronic graft-versus-host disease after human leukocyte antigen-identical sibling transplantation. Blood 2001; 98: 3221-3227.
57. + selected cells from peripheral blood from human leukocyte antigen-identical siblings; detrimental effect of a high number of donor CD34+ cells? Blood 2001; 98: 2352-2357.
58. Vora AJ, Toh CH, Pel J, Greaves M. Use of granulocyte colony-stimulating factor (G-CSF) for mobilizing peripheral blood stem cells: risk of mobilizing clonal myeloma cells in patients with bone marrow infiltration. Br J Haematol 1994; 86: 180-182.
59. Brugger W, Bross KJ, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 636-640.
60. Lemoli RM, Fortuna A, Motta MR et al. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of multiple myeloma patients; positive selection and transplantation of enriched CD34 + cells to remove circulating tumor cells. Blood 1996; 87:1625-1634.
61. Franklin WA, Glaspy J, Pflaumer SM et al. Incidence of tumor-cell contamination in leukapheresis products of breast cancer patients mobilized with stem cell factor and granulocyte colony-stimulating factor (G-CSF) or with G-CSF alone. Blood 1999; 94: 340-347.
62. Gazitt Y, Shaughnessy P, Liu Q. Differential mobilization of CD34+ cells and lymphoma cells in non-Hodgkin's lymphoma patients mobilized with different growth factors. J Hematother Stem Cell Res 2001; 10: 167-176.
63. Sugrue MW, Williams K, Pollock BH et al. Characterization and outcome of 'hard to mobilize' lymphoma patients undergoing autologous stem cell transplantation. Leuk Lymphoma 2000; 39: 509-519.
64. Stockerl-Goldstein KE, Reddy SA, Horning SF et al. Favorable treatment outcome in non-Hodgkin's lymphoma patients with 'poor' mobilization of peripheral blood progenitor cells. Biol Blood Marrow Transplant 2000; 6: 506-512.
65. Kessinger A, Bierman PJ, Cowles MK et al. Mobilized versus non-mobilized peripheral stem cell transplantation after high dose therapy for low grade non-Hodgkin lymphoma. Cancer Res Ther Control 1998; 5: 113-119.
66. Boccadoro M, Omede P, Dominietto A et al. Multiple myeloma: the number of reinfused plasma cells does not influence outcome of patients treated with intensified chemotherapy and PBPC support. Bone Marrow Transplant 2000; 25: 25-29.
67. Cooper BW, Moss TH, Ross AA et al. Occult tumor contamination of hematopoietic stem-cell products does not affect clinical outcome of autologous transplantation in patients with metastatic breast cancer. J Clin Oncol 1998; 16: 3509-3517.
68. Watts MJ, Ings SJ, Flynn M et al. Remobilization of patients who fail to achieve minimal progenitor thresholds at the first attempt is clinically worthwhile. Br J Haematol 2000; 111: 287-291.
69. Perry AR, Watts MJ, Peniket AH et al. Progenitor cell yields are frequently poor in patients with histologically indolent lymphomas especially when mobilized within 6 months of previous chemotherapy. Bone Marrow Transplant 1998; 21: 1201-1205.
70. Brugger W, Bross K, Frisch J et al. Mobilization of peripheral blood progenitors by sequential administration of interleukin-3 and granulocyte-macrophage colony-stimulating factor following polychemotherapy with etoposide, ifosfamide and cisplatin. Blood 1992; 79: 1193-1200.
71. Haas R, Mohle R, Fruehauf S et al. Patient characteristics associated with successful mobilizing and autografting of peripheral blood progenitor cells in malignant lymphoma. Blood 1992; 83: 3787-3794.
72. + NK cell count independently predicts autologous blood stem cell mobilization. Bone Marrow Transplant 2001; 27: 1237-1243.
73. Zimmerman TM, Michelson GC, Mick R et al. Timing of platelet recovery is associated with adequacy of leukapheresis product yield after cyclophosphamide and G-CSF in patients with lymphoma. J Clin Apheresis 1999; 14: 31-34.
74. Kotasek D, Shepherd KM, Sage RE et al. Factors affecting blood stem cell collections following high-dose cyclophosphamide mobilization in lymphoma, myeloma and solid tumors. Bone Marrow Transplant 1992; 9: 11-17.
75. Koumakis G, Vassiolmanolakis M, Hatzichristou H et al. Predictive factors affecting mobilization and peripheral blood stem cell collection using single apheresis for rescuing patients after high-dose chemotherapy in various malignancies. Bone Marrow Transplant 1996; 18: 1065-1072.
76. Canales MA, Fernandez-Jimenez MC, Martin A et al. Identification of factors associated with poor peripheral blood progenitor cell mobilization in Hodgkin's disease. Haematologica 2001; 86: 494-498.
77. Fruehauf S, Haas R, Conradt C et al. Peripheral blood progenitor cell (PBPC) counts during steady state hematopoiesis allow to estimate the yield of mobilized PBPC after filgrastim (R-met HuG-CSF) supported cytotoxic chemotherapy. Blood 1995; 85: 2619-2626.
78. Demirkazik A, Kessinger A, Lynch J et al. Effect of prior therapy and bone marrow metastases on progenitor cell content of blood stem cell harvests in breast cancer patients. Biol Blood Marrow Transplant 2002; 8: 268-272.
79. Benekli M, Shafi F, Qureshi A et al. The effect of rituximab on peripheral blood stem cell mobilization in non-Hodgkin's lymphoma. Proc ASCO 2002; 21: 417a (Abstr. 1666).
80. Voso MT, Pantel G, Weis M et al. In vivo depletion of B cells using a combination of high-dose cytosine arabinoside/mitoxantrone and rituximab for autografting in patients with non-Hodgkin's lymphoma. Br J Haematol 2000; 109: 729-735.
81. Bensinger WI, Clift RA, Anasetti C et al. Transplantation of allogeneic peripheral blood stem cells mobilized by recombinant human granulocyte colony stimulating factor. Stem Cells 1996; 14: 90-105.
82. Wiesneth M, Schreiner T, Friedrich A et al. Mobilization and collection of allogeneic peripheral blood progenitor cells for transplantation. Bone Marrow Transplant 1998; 21 (Suppl. 3): 21-24.
83. Bishop MR, Tarantolo SR, Bierman PH et al. Predictive factors for the identification of allogeneic blood stem cell donors as 'poor mobilizers' prior to stem cell collections. Blood 1997; 90 (Suppl. 1): 592a (Abstr. 2632).
84. Anderlini P, Korbling M. The use of mobilized peripheral blood stem cells from normal donors for allografting. Stem Cells 1997; 15: 9-17.
85. Holm M, Hokland P. Not all healthy donors mobilize hematopoietic progenitor cells sufficiently after G-CSF administration to allow for subsequent CD34 purification of the leukapheresis product. J Hematother 1998; 7: 111-113 (Letter).
86. Roberts AW, Foote S, Alexander WS et al. Genetic influences determining progenitor cell mobilization and leukocytosis induced by granulocyte colony-stimulating factor. Blood 1997; 89: 2736-2744.
87. Kessinger A, Mann S, Murphy BO et al. Circulating factors may be responsible for strain-specific responses to mobilizing cytokines. Exp Hematol 2001; 29: 775-778.
88. Sharp JG, Kessinger A, Clausen SR et al. Concurrent partial body radiation prevents cytokine mobilization of blood progenitor cells: an effect mediated by a circulating factor. J Hematother 1998; 7: 343-349.
89. Kessinger A, Sharp JG. Mobilization of blood stem cells. Stem Cells 1998; 16 (Suppl. 1): 139-144.
90. Bociek RG, Lynch JC, Yee GC et al. Outcome and factors associated with slow mobilization of peripheral blood progenitor cells (PBPC) in patients undergoing autologous transplantation for non-Hodgkin's lymphoma (NHL). Blood 2001; 98: 861a (Abstr. 3575).
91. Papayannopoulou T, Nakamoto B. Peripheralization of hematopoietic progenitors in primates treated with anti-VLA4 integrin. Proc Natl Acad Sci USA 1993; 90: 9374-938.
92. Gazitt Y, Shaughnessy P, Liu Q. Expression of adhesion molecules on CD34 + cells in peripheral blood of non-Hodgkin's lymphoma patients mobilized with different growth factors. Stem Cells 2001; 19: 134-143.
93. Aiuti A, Webb IJ, Bleul C et al. The chemokine SDF-1 is a chemoattractant for human CD34 + hematopoietic progenitor cells and provides a new mechanism to explain the mobilization of CD34+ progenitors to peripheral blood. J Exp Med 1997; 185: 111-120.
94. Gazitt Y, Liu Q. Plasma levels of SDF-1 and expression of SDF-1 receptor on CD34+ cells in mobilized peripheral blood of non-Hodgkin's lymphoma patients. Stem Cells 2001; 19: 35-45.
95. Gazitt Y, Liu Q. High steady-state plasma levels of flt3-ligand in the peripheral blood is a good predictor for poor mobilization of CD34+ PBSC in patients undergoing high-dose chemotherapy and stem cell rescue. J Hematother Stem Cell Res 2000; 9: 285-293.
96. Dettke M, Jurko S, Ruger BM et al. Increased serum flt3-ligand in healthy donors undergoing granulocyte colony-stimulating factor-induced peripheral stem cell mobilization. J Hematother Stem Cell Res 2001; 10: 317-320.
97. Fraipont V, Sautois B, Baudoux E et al. Successful mobilization of peripheral blood HPCs with G-CSF alone in patients failing to achieve sufficient numbers of CD34+ cells and/or CFU-GM with chemotherapy and G-CSF. Transfusion 2000; 40: 339-347.
98. Weaver CH, Tauer K, Zhen B et al. Second attempts at mobilization of peripheral blood stem cells in patients with initial low CD34+ cell yields. J Hematother 1998; 7: 241-249.
99. Bashey A, Corringham S, Gilpin E et al. Simultaneous administration of G-CSF and GM-CSF for re-mobilization in patients with inadequate initial progenitor cell collections for autologous transplantation. Cytotherapy 2000; 2: 195-200.
100. Rick O, Beyer J, Kingreen D et al. Successful autologous bone marrow rescue in patients who failed peripheral blood stem cell mobilization. Ann Hematol 2000; 79: 681-686.
101. Kessinger A, Armitage JO, Landmark JD et al. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following marrow ablative therapy. Blood 1988; 71: 723-727.
102. Comenzo R, Malachowski M, Miller K et al. Large-volume leukapheresis for collection of mononuclear cells for hematopoietic rescue in Hodgkin's disease. Transfusion 1995; 35: 42-45.
103. Lie AK, Rawling TP, Bayly JL, To LB. Progenitor cell yield in sequential blood stem cell mobilization in the same patients: insights into chemotherapy dose escalation and combination of haematopoietic growth factor and chemotherapy. Br J Haematol 1996; 95: 39-44.
104. Vallejo C, Lozano ML, Ortuno F et al. Re-mobilization of peripheral blood progenitor cells in a short time interval fails to achieve effective progenitor cell yields. Bone Marrow Transplant 2000; 26: 351-352.
105. Anderlini P, Lauppe J, Przepiorka D et al. Peripheral blood stem cell apheresis in normal donors: feasibility and yield of second collections. Br J Haematol 1997; 96: 415-427.
106. Tichelli A, Passweg J, Hoffmann T et al. Repeated peripheral stem cell mobilization in healthy donors: time-dependent changes in mobilization efficiency. Br J Haematol 1999; 106: 152-158.